Phathom Pharmaceuticals, Inc. Gross Profit

Gross Profit of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Profit growth rates and interactive chart. Gross profit is a company's net sales revenue minus its cost of goods sold (or cost of revenue). In other words, it is the sales revenue a company retains after incurring the direct costs associated with producing the goods it sells, and the services it provides.

Highlights and Quick Summary

  • Gross Profit for the quarter ending June 29, 2021 was $-131 Thousand (a 4.8% increase compared to previous quarter)
  • Year-over-year quarterly Gross Profit increased by 48.86%
  • Annual Gross Profit for 2020 was $-300 Thousand (a 3650.0% increase from previous year)
  • Twelve month Gross Profit ending June 29, 2021 was $-427 Thousand (a 14.48% increase compared to previous quarter)
  • Twelve month trailing Gross Profit increased by 91.48% year-over-year
Trailing Gross Profit for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-427 Thousand $-373 Thousand $-300 Thousand $-223 Thousand
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Profit of Phathom Pharmaceuticals, Inc.

Most recent Gross Profitof PHAT including historical data for past 10 years.

Interactive Chart of Gross Profit of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Gross Profit for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.13 $-0.13
2020 $-0.08 $-0.09 $-0.08 $-0.05 $-0.3
2019 $-0.01 $-0.01

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.